AZD 4205 is a targeted therapeutic agent primarily utilized in oncology, particularly for non-small cell lung cancer (NSCLC). It functions as a selective inhibitor of EGFR tyrosine kinase, designed to target mutations in the epidermal growth factor receptor (EGFR) found in certain NSCLC patients. By inhibiting signaling pathways that promote cancer cell proliferation and spread, it helps slow or halt disease progression. This compound is under investigation in clinical trials to evaluate its efficacy, safety, and tolerability, aiming to provide a novel treatment option for malignancies resistant to conventional therapies. Additionally, AZD 4205 is being studied for combination use with other anticancer drugs to enhance therapeutic outcomes.